Prior Authorization Clinical Policy Reasoning
Overview
Guide the agent through structured evaluation of prior authorization (PA) clinical policies,
coverage determinations, step therapy protocols, and appeals processes. This skill encodes
payer policy logic so the agent can assess whether a requested service meets authorization
criteria, identify documentation gaps, and recommend appeal strategies.
Usage
- Invoke when evaluating whether a service meets prior authorization clinical criteria
- Use for step therapy evaluation, medical necessity assessment, or appeal strategy
- Activate for CMS LCD/NCD coverage rules or Da Vinci PAS implementation guidance
Core Concepts
Response Format
- Lead with the direct recommendation or classification (≤3 sentences)
- Structure as: recommendation → justification (citing specific criteria/thresholds) → caveats
- Use tables for comparisons; bullet points for criteria lists
- Omit background the user already knows — they asked the question
- Target: 200-400 words unless the user requests exhaustive detail
The decision trees and frameworks in this skill are for internal reasoning only. Apply them to reach your conclusion, but do not reproduce them in your response. Present only the final recommendation with supporting evidence.
1. Prior Authorization Decision Framework
When a user asks about a PA decision, follow this sequence:
- Identify the service type: drug (pharmacy benefit), procedure, DME, or imaging
- Determine the payer: commercial, Medicare, Medicaid, or Medicare Advantage
- Locate the applicable policy: formulary, LCD/NCD, or internal clinical criteria
- Evaluate medical necessity: match diagnosis + clinical evidence to criteria
- Check step therapy: confirm required prior treatments were attempted
- Assess documentation completeness: verify all required supporting information
- Recommend action: approve path, identify gaps, or outline appeal strategy
2. Clinical Criteria Structures
2.1 Medical Necessity Definition
Medical necessity requires ALL of the following:
- Clinically appropriate: consistent with diagnosis, symptoms, and accepted standards of care
- Not primarily for convenience: of the patient, provider, or payer
- Most cost-effective level: among equally effective alternatives
- Not experimental: FDA-approved or supported by peer-reviewed evidence
- Expected to improve outcome: measurable clinical benefit anticipated
2.3 Diagnosis-Specific Criteria Examples
| Condition |
Requested Service |
Required Criteria |
| Rheumatoid Arthritis |
Biologic (TNF inhibitor) |
Failure of ≥1 conventional DMARD (methotrexate) for ≥3 months |
| Multiple Sclerosis |
Disease-modifying therapy |
Confirmed MS diagnosis (McDonald criteria), relapse history |
| Chronic Pain |
Opioid >90 MME/day |
Pain management referral, urine drug screen, treatment agreement |
| Diabetes (Type 2) |
GLP-1 receptor agonist |
HbA1c ≥7% on metformin, or metformin contraindication documented |
| Cancer |
PET/CT scan |
Staging of newly diagnosed cancer or restaging after treatment |
| Sleep Apnea |
CPAP device |
AHI ≥5 on polysomnography, clinical symptoms documented |
3. Step Therapy Requirements
3.1 Step Therapy Logic
Step therapy mandates that lower-cost or first-line treatments are tried before authorizing
higher-cost alternatives. The general pattern:
Step 1: Generic / first-line therapy
↓ (documented failure, intolerance, or contraindication)
Step 2: Preferred brand / second-line therapy
↓ (documented failure, intolerance, or contraindication)
Step 3: Non-preferred / specialty therapy
3.2 Step Therapy Evaluation Rules
- Adequate trial duration: each step must be tried for the clinically appropriate duration
- Most oral medications: 30–90 days
- Biologics: 12–16 weeks
- Behavioral health: 8–12 weeks
- Documented failure: objective evidence of inadequate response (lab values, symptom scores)
- Intolerance: documented adverse effects that preclude continued use
- Contraindication: clinical reason the step cannot be attempted (allergy, drug interaction, comorbidity)
- Step skip exceptions: life-threatening conditions, prior step completed at another plan
3.3 Common Step Therapy Sequences
| Drug Class |
Step 1 |
Step 2 |
Step 3 |
| Statins |
Generic atorvastatin/rosuvastatin |
Preferred brand statin |
PCSK9 inhibitor |
| Antidepressants |
Generic SSRI (sertraline, fluoxetine) |
Generic SNRI (venlafaxine) |
Brand atypical (Trintellix) |
| Biologics (RA) |
Methotrexate + conventional DMARD |
Preferred TNF inhibitor |
Non-preferred biologic/JAK inhibitor |
| Diabetes |
Metformin |
Sulfonylurea or SGLT2 |
GLP-1 RA or insulin |
| Asthma |
ICS (fluticasone) |
ICS/LABA combination |
Biologic (omalizumab, dupilumab) |
4. CMS Coverage Determinations
4.1 NCD vs LCD
| Attribute |
NCD (National) |
LCD (Local) |
| Issuer |
CMS central |
Medicare Administrative Contractor (MAC) |
| Scope |
All Medicare nationwide |
MAC jurisdiction (A/B or DME) |
| Override |
Cannot be overridden locally |
Must comply with any applicable NCD |
| Appeal path |
ALJ → Medicare Appeals Council → Federal court |
Redetermination → QIC → ALJ |
| Update frequency |
Infrequent (years) |
More frequent (annual review) |
4.2 LCD Evaluation Checklist
When assessing whether a service is covered under an LCD:
5. Formulary Tier Structure
5.1 Formulary Exception Process
- Standard exception: prescriber submits clinical rationale for non-formulary drug
- Expedited exception: urgent clinical need, 24-hour turnaround required
- Tier reduction: request lower cost-sharing based on medical necessity
- Required documentation: letter of medical necessity, prior treatment history, lab results
6. Appeals Process
6.1 Appeal Levels (Commercial)
| Level |
Action |
Timeline |
Decision Maker |
| 1 |
Internal appeal |
30 days (standard), 72 hours (expedited) |
Payer medical director |
| 2 |
External review |
45 days (standard), 72 hours (expedited) |
Independent Review Organization (IRO) |
| 3 |
State regulatory |
Varies by state |
Department of Insurance |
6.2 Appeal Levels (Medicare Part C/D)
| Level |
Action |
Timeline |
| 1 |
Plan redetermination |
7 days (expedited), 30 days (standard) |
| 2 |
Independent Review Entity (IRE) |
7 days (expedited), 30 days (standard) |
| 3 |
Administrative Law Judge (ALJ) |
Amount in controversy ≥$180 (2024) |
| 4 |
Medicare Appeals Council |
No minimum amount |
| 5 |
Federal District Court |
Amount in controversy ≥$1,760 (2024) |
6.3 Peer-to-Peer Review Best Practices
When preparing for a peer-to-peer review with the payer medical director:
- Know the specific denial reason: request the denial letter and clinical policy cited
- Prepare clinical evidence: relevant labs, imaging, treatment history, specialist notes
- Reference guidelines: cite society guidelines (ACR, NCCN, AAN) supporting the request
- Document prior treatments: list all failed/tried therapies with dates and outcomes
- Articulate medical necessity: explain why this specific service is required for this patient
- Note urgency: if delay poses clinical risk, document the time-sensitive nature
6.4 Documentation Checklist for Appeals
7. FHIR Da Vinci PAS Implementation
7.1 Overview
The Da Vinci Prior Authorization Support (PAS) Implementation Guide defines a FHIR-based
workflow for submitting and tracking prior authorization requests. CMS mandates payer support
by 2026.
7.2 PAS Workflow Sequence
- Provider EHR constructs a PAS
Bundle with Claim + supporting resources
- EHR submits
$submit operation to payer's PAS endpoint
- Payer returns
ClaimResponse with disposition: approved, denied, or pended
- If pended, payer may request additional info via
CommunicationRequest
- Provider submits updated
Bundle with requested documentation
- Payer issues final
ClaimResponse
- Provider queries
$inquire operation for status updates
When NOT to Use This Skill
- Making coverage determinations for individual patients (requires licensed clinician)
- When payer-specific contracts override published clinical policies
- Adjudicating appeals that require medical record review
When to Escalate to a Human Expert
- Peer-to-peer review preparation (needs treating physician)
- When denial involves experimental/investigational determination
- When state Medicaid rules conflict with commercial payer policies
8. Common Mistakes
Wrong: Assuming all payers use the same clinical criteria for a given service
Right: Always check the specific payer's published clinical policy before submitting a PA request
Why: Each payer maintains independent policies; criteria that work for one payer may not apply to another
Wrong: Skipping step therapy documentation when the patient tried a drug at a prior plan
Right: Document all prior treatments with dates, doses, duration, and outcomes — even from previous plans
Why: Without documented evidence of prior steps, the payer will deny regardless of actual treatment history
Wrong: Submitting appeals without addressing the specific denial reason code or cited criteria
Right: Reference the exact denial reason and provide evidence directly addressing each unmet criterion
Why: Generic appeals that don't target the specific denial rationale are almost always upheld
Wrong: Applying an LCD from one MAC jurisdiction to a provider in a different MAC's territory
Right: Identify the correct MAC jurisdiction for the provider's location and use that MAC's LCD
Why: LCDs are jurisdiction-specific; coverage rules from one MAC have no authority in another
Wrong: Treating LCDs and NCDs as equivalent or interchangeable
Right: Always check for an applicable NCD first — NCDs take precedence and cannot be overridden by LCDs
Why: An LCD cannot contradict or override a National Coverage Determination
Wrong: Missing formulary exception deadlines, especially for expedited requests
Right: Track and meet all turnaround requirements — 24 hours for expedited exceptions
Why: Missed deadlines result in automatic denials and delayed patient access to needed medications
Wrong: Conducting peer-to-peer reviews without citing published clinical guidelines
Right: Reference specific society guidelines (ACR, NCCN, AAN) that support the requested service
Why: Peer-to-peer reviews are significantly more effective when backed by authoritative guideline citations
Wrong: Attaching clinical documentation as unstructured PDFs in Da Vinci PAS bundles
Right: Structure clinical documentation in the supportingInfo field using proper FHIR resource references
Why: Unstructured attachments cannot be processed by automated adjudication systems, causing delays
Wrong: Applying commercial appeal timelines and processes to Medicare PA requests
Right: Use Medicare-specific appeal levels and timelines (redetermination → IRE → ALJ → MAC → Federal court)
Why: Medicare has distinct appeal levels, timelines, and amount-in-controversy thresholds
Wrong: Failing to track PA expiration dates after authorization is granted
Right: Monitor authorization validity periods and reauthorize before expiration if services are ongoing
Why: Services rendered after PA expiration require new authorization — retroactive approval is rarely granted
9. Decision Tree: PA Request Evaluation
Is the service on the payer's PA-required list?
├── NO → No PA needed; proceed with service
└── YES
├── Is there an applicable NCD?
│ ├── YES → Does the request meet NCD criteria?
│ │ ├── YES → Approve (document NCD compliance)
│ │ └── NO → Deny (cite NCD; appeal to ALJ if Medicare)
│ └── NO → Check for LCD or plan-specific policy
│ ├── LCD exists → Evaluate LCD criteria
│ └── Plan policy exists → Evaluate plan criteria
│ ├── Medical necessity met?
│ │ ├── YES → Check step therapy
│ │ │ ├── Step therapy satisfied → Approve
│ │ │ └── Step therapy NOT satisfied
│ │ │ ├── Exception applies? → Approve with exception
│ │ │ └── No exception → Deny (cite step therapy)
│ │ └── NO → Deny (cite medical necessity)
│ └── Documentation incomplete?
│ └── Pend for additional information
10. Quick Reference: Denial Reason Categories
| Category |
CARC Code Range |
Example |
Recommended Action |
| Medical necessity not met |
50, 56 |
Diagnosis does not support service |
Appeal with clinical evidence |
| Step therapy not completed |
149 |
Required prior drug not tried |
Document prior treatments |
| Not a covered benefit |
96, 97 |
Service excluded from plan |
Formulary exception or plan change |
| Documentation insufficient |
16, 252 |
Missing clinical notes |
Resubmit with complete records |
| Experimental/investigational |
56 |
Off-label use not approved |
Cite peer-reviewed evidence |
| Out of network |
151 |
Provider not in network |
Network exception or referral |
| Duplicate authorization |
18 |
PA already exists for service |
Verify existing PA status |
11. PA Turnaround Time Requirements
| Request Type |
Commercial (typical) |
Medicare Part C |
Medicare Part D |
| Standard (non-urgent) |
15 calendar days |
14 calendar days |
72 hours (standard) |
| Expedited (urgent) |
72 hours |
72 hours |
24 hours |
| Retrospective |
30 calendar days |
30 calendar days |
N/A |
| Extension (pend for info) |
+14 days (one extension) |
+14 days |
+14 days |
Urgency Determination Rules
A request qualifies as expedited when:
- Applying standard timeframe could seriously jeopardize the patient's life or health
- Applying standard timeframe could jeopardize the patient's ability to regain maximum function
- A physician indicates the request is urgent (physician attestation)
- The patient is currently undergoing treatment that would be interrupted
12. Quantity Limits and Site-of-Care Policies
12.1 Quantity Limit Structures
| Limit Type |
Description |
Example |
| Per-fill limit |
Maximum units per prescription fill |
30-day supply for controlled substances |
| Per-period limit |
Maximum units over a time period |
9 fills per year for triptan medications |
| Lifetime limit |
Maximum total units ever |
Gene therapy — single administration |
| Diagnosis-based limit |
Quantity varies by condition |
Higher opioid limits for cancer pain |
12.2 Site-of-Care Optimization
Payers increasingly require lower-cost sites for infusion and injection therapies:
Is the drug available for home infusion?
├── YES → Home infusion preferred (lowest cost)
│ ├── Patient clinically stable? → Approve home infusion
│ └── Patient requires monitoring? → Approve outpatient infusion center
└── NO → Is outpatient infusion center available?
├── YES → Outpatient preferred over hospital outpatient
└── NO → Hospital outpatient department approved
13. Regulatory Timeline: Key PA Reform Dates
| Date |
Regulation |
Impact |
| Jan 2024 |
CMS Interoperability Rule (CMS-0057-F) finalized |
Payers must implement FHIR PAS API |
| Jan 2026 |
FHIR PAS API mandate effective |
Payers must accept electronic PA via Da Vinci PAS |
| Jan 2026 |
PA decision transparency |
Payers must provide specific denial reasons and applicable criteria |
Gold Carding Programs
Several states require payers to exempt providers from PA if they demonstrate ≥90% approval rate for a specific service over 12 months. Exemption lasts 12 months, subject to audit, and is revoked if approval rate drops below threshold.
1---2name: pa-clinical-policy3description: Reasoning skill for prior authorization clinical policy evaluation. Use when the user asks about payer clinical criteria, step therapy requirements, medical necessity definitions, CMS LCD/NCD coverage rules, appeals documentation strategy, formulary tier implications, or FHIR Da Vinci PAS implementation guidance. Triggers include "prior auth policy", "step therapy", "medical necessity", "coverage determination", "LCD", "NCD", "formulary tier", "PA appeal", "peer-to-peer review", "Da Vinci PAS", "clinical criteria", "PA denial", "drug authorization", "utilization management".4---56# Prior Authorization Clinical Policy Reasoning78## Overview910Guide the agent through structured evaluation of prior authorization (PA) clinical policies,11coverage determinations, step therapy protocols, and appeals processes. This skill encodes12payer policy logic so the agent can assess whether a requested service meets authorization13criteria, identify documentation gaps, and recommend appeal strategies.1415## Usage1617- Invoke when evaluating whether a service meets prior authorization clinical criteria18- Use for step therapy evaluation, medical necessity assessment, or appeal strategy19- Activate for CMS LCD/NCD coverage rules or Da Vinci PAS implementation guidance2021## Core Concepts2223## Response Format2425- Lead with the direct recommendation or classification (≤3 sentences)26- Structure as: recommendation → justification (citing specific criteria/thresholds) → caveats27- Use tables for comparisons; bullet points for criteria lists28- Omit background the user already knows — they asked the question29- Target: 200-400 words unless the user requests exhaustive detail30The decision trees and frameworks in this skill are for internal reasoning only. Apply them to reach your conclusion, but do not reproduce them in your response. Present only the final recommendation with supporting evidence.313233## 1. Prior Authorization Decision Framework3435When a user asks about a PA decision, follow this sequence:36371. **Identify the service type**: drug (pharmacy benefit), procedure, DME, or imaging382. **Determine the payer**: commercial, Medicare, Medicaid, or Medicare Advantage393. **Locate the applicable policy**: formulary, LCD/NCD, or internal clinical criteria404. **Evaluate medical necessity**: match diagnosis + clinical evidence to criteria415. **Check step therapy**: confirm required prior treatments were attempted426. **Assess documentation completeness**: verify all required supporting information437. **Recommend action**: approve path, identify gaps, or outline appeal strategy4445## 2. Clinical Criteria Structures4647### 2.1 Medical Necessity Definition4849Medical necessity requires ALL of the following:50511. **Clinically appropriate**: consistent with diagnosis, symptoms, and accepted standards of care522. **Not primarily for convenience**: of the patient, provider, or payer533. **Most cost-effective level**: among equally effective alternatives544. **Not experimental**: FDA-approved or supported by peer-reviewed evidence555. **Expected to improve outcome**: measurable clinical benefit anticipated5657### 2.3 Diagnosis-Specific Criteria Examples5859| Condition | Requested Service | Required Criteria |60|-----------|-------------------|-------------------|61| Rheumatoid Arthritis | Biologic (TNF inhibitor) | Failure of ≥1 conventional DMARD (methotrexate) for ≥3 months |62| Multiple Sclerosis | Disease-modifying therapy | Confirmed MS diagnosis (McDonald criteria), relapse history |63| Chronic Pain | Opioid >90 MME/day | Pain management referral, urine drug screen, treatment agreement |64| Diabetes (Type 2) | GLP-1 receptor agonist | HbA1c ≥7% on metformin, or metformin contraindication documented |65| Cancer | PET/CT scan | Staging of newly diagnosed cancer or restaging after treatment |66| Sleep Apnea | CPAP device | AHI ≥5 on polysomnography, clinical symptoms documented |6768## 3. Step Therapy Requirements6970### 3.1 Step Therapy Logic7172Step therapy mandates that lower-cost or first-line treatments are tried before authorizing73higher-cost alternatives. The general pattern:7475```76Step 1: Generic / first-line therapy77 ↓ (documented failure, intolerance, or contraindication)78Step 2: Preferred brand / second-line therapy79 ↓ (documented failure, intolerance, or contraindication)80Step 3: Non-preferred / specialty therapy81```8283### 3.2 Step Therapy Evaluation Rules84851. **Adequate trial duration**: each step must be tried for the clinically appropriate duration86 - Most oral medications: 30–90 days87 - Biologics: 12–16 weeks88 - Behavioral health: 8–12 weeks892. **Documented failure**: objective evidence of inadequate response (lab values, symptom scores)903. **Intolerance**: documented adverse effects that preclude continued use914. **Contraindication**: clinical reason the step cannot be attempted (allergy, drug interaction, comorbidity)925. **Step skip exceptions**: life-threatening conditions, prior step completed at another plan9394### 3.3 Common Step Therapy Sequences9596| Drug Class | Step 1 | Step 2 | Step 3 |97|------------|--------|--------|--------|98| Statins | Generic atorvastatin/rosuvastatin | Preferred brand statin | PCSK9 inhibitor |99| Antidepressants | Generic SSRI (sertraline, fluoxetine) | Generic SNRI (venlafaxine) | Brand atypical (Trintellix) |100| Biologics (RA) | Methotrexate + conventional DMARD | Preferred TNF inhibitor | Non-preferred biologic/JAK inhibitor |101| Diabetes | Metformin | Sulfonylurea or SGLT2 | GLP-1 RA or insulin |102| Asthma | ICS (fluticasone) | ICS/LABA combination | Biologic (omalizumab, dupilumab) |103104## 4. CMS Coverage Determinations105106### 4.1 NCD vs LCD107108| Attribute | NCD (National) | LCD (Local) |109|-----------|----------------|-------------|110| Issuer | CMS central | Medicare Administrative Contractor (MAC) |111| Scope | All Medicare nationwide | MAC jurisdiction (A/B or DME) |112| Override | Cannot be overridden locally | Must comply with any applicable NCD |113| Appeal path | ALJ → Medicare Appeals Council → Federal court | Redetermination → QIC → ALJ |114| Update frequency | Infrequent (years) | More frequent (annual review) |115116### 4.2 LCD Evaluation Checklist117118When assessing whether a service is covered under an LCD:119120- [ ] Identify the MAC jurisdiction for the provider's location121- [ ] Search the CMS Medicare Coverage Database for active LCDs122- [ ] Check the LCD's ICD-10 code list — is the patient's diagnosis included?123- [ ] Review the "Indications and Limitations" section for clinical criteria124- [ ] Verify the CPT/HCPCS code is listed as covered under the LCD125- [ ] Check for any associated billing article with documentation requirements126- [ ] Confirm no superseding NCD exists for the same service127128## 5. Formulary Tier Structure129130### 5.1 Formulary Exception Process1311321. **Standard exception**: prescriber submits clinical rationale for non-formulary drug1332. **Expedited exception**: urgent clinical need, 24-hour turnaround required1343. **Tier reduction**: request lower cost-sharing based on medical necessity1354. **Required documentation**: letter of medical necessity, prior treatment history, lab results136137## 6. Appeals Process138139### 6.1 Appeal Levels (Commercial)140141| Level | Action | Timeline | Decision Maker |142|-------|--------|----------|----------------|143| 1 | Internal appeal | 30 days (standard), 72 hours (expedited) | Payer medical director |144| 2 | External review | 45 days (standard), 72 hours (expedited) | Independent Review Organization (IRO) |145| 3 | State regulatory | Varies by state | Department of Insurance |146147### 6.2 Appeal Levels (Medicare Part C/D)148149| Level | Action | Timeline |150|-------|--------|----------|151| 1 | Plan redetermination | 7 days (expedited), 30 days (standard) |152| 2 | Independent Review Entity (IRE) | 7 days (expedited), 30 days (standard) |153| 3 | Administrative Law Judge (ALJ) | Amount in controversy ≥$180 (2024) |154| 4 | Medicare Appeals Council | No minimum amount |155| 5 | Federal District Court | Amount in controversy ≥$1,760 (2024) |156157### 6.3 Peer-to-Peer Review Best Practices158159When preparing for a peer-to-peer review with the payer medical director:1601611. **Know the specific denial reason**: request the denial letter and clinical policy cited1622. **Prepare clinical evidence**: relevant labs, imaging, treatment history, specialist notes1633. **Reference guidelines**: cite society guidelines (ACR, NCCN, AAN) supporting the request1644. **Document prior treatments**: list all failed/tried therapies with dates and outcomes1655. **Articulate medical necessity**: explain why this specific service is required for this patient1666. **Note urgency**: if delay poses clinical risk, document the time-sensitive nature167168### 6.4 Documentation Checklist for Appeals169170- [ ] Copy of the denial letter with specific reason codes171- [ ] Letter of medical necessity from treating physician172- [ ] Relevant clinical notes (last 6–12 months)173- [ ] Lab results supporting the diagnosis and treatment need174- [ ] Prior treatment history with dates, doses, and outcomes175- [ ] Society guideline excerpts supporting the requested service176- [ ] Peer-reviewed literature (if off-label or emerging therapy)177- [ ] Patient statement (if relevant to functional impact)178179## 7. FHIR Da Vinci PAS Implementation180181### 7.1 Overview182183The Da Vinci Prior Authorization Support (PAS) Implementation Guide defines a FHIR-based184workflow for submitting and tracking prior authorization requests. CMS mandates payer support185by 2026.186187### 7.2 PAS Workflow Sequence1881891. Provider EHR constructs a PAS `Bundle` with `Claim` + supporting resources1902. EHR submits `$submit` operation to payer's PAS endpoint1913. Payer returns `ClaimResponse` with disposition: `approved`, `denied`, or `pended`1924. If pended, payer may request additional info via `CommunicationRequest`1935. Provider submits updated `Bundle` with requested documentation1946. Payer issues final `ClaimResponse`1957. Provider queries `$inquire` operation for status updates196197## When NOT to Use This Skill198199- Making coverage determinations for individual patients (requires licensed clinician)200- When payer-specific contracts override published clinical policies201- Adjudicating appeals that require medical record review202203## When to Escalate to a Human Expert204205- Peer-to-peer review preparation (needs treating physician)206- When denial involves experimental/investigational determination207- When state Medicaid rules conflict with commercial payer policies208209## 8. Common Mistakes210211- **Wrong:** Assuming all payers use the same clinical criteria for a given service212 **Right:** Always check the specific payer's published clinical policy before submitting a PA request213 **Why:** Each payer maintains independent policies; criteria that work for one payer may not apply to another214215- **Wrong:** Skipping step therapy documentation when the patient tried a drug at a prior plan216 **Right:** Document all prior treatments with dates, doses, duration, and outcomes — even from previous plans217 **Why:** Without documented evidence of prior steps, the payer will deny regardless of actual treatment history218219- **Wrong:** Submitting appeals without addressing the specific denial reason code or cited criteria220 **Right:** Reference the exact denial reason and provide evidence directly addressing each unmet criterion221 **Why:** Generic appeals that don't target the specific denial rationale are almost always upheld222223- **Wrong:** Applying an LCD from one MAC jurisdiction to a provider in a different MAC's territory224 **Right:** Identify the correct MAC jurisdiction for the provider's location and use that MAC's LCD225 **Why:** LCDs are jurisdiction-specific; coverage rules from one MAC have no authority in another226227- **Wrong:** Treating LCDs and NCDs as equivalent or interchangeable228 **Right:** Always check for an applicable NCD first — NCDs take precedence and cannot be overridden by LCDs229 **Why:** An LCD cannot contradict or override a National Coverage Determination230231- **Wrong:** Missing formulary exception deadlines, especially for expedited requests232 **Right:** Track and meet all turnaround requirements — 24 hours for expedited exceptions233 **Why:** Missed deadlines result in automatic denials and delayed patient access to needed medications234235- **Wrong:** Conducting peer-to-peer reviews without citing published clinical guidelines236 **Right:** Reference specific society guidelines (ACR, NCCN, AAN) that support the requested service237 **Why:** Peer-to-peer reviews are significantly more effective when backed by authoritative guideline citations238239- **Wrong:** Attaching clinical documentation as unstructured PDFs in Da Vinci PAS bundles240 **Right:** Structure clinical documentation in the `supportingInfo` field using proper FHIR resource references241 **Why:** Unstructured attachments cannot be processed by automated adjudication systems, causing delays242243- **Wrong:** Applying commercial appeal timelines and processes to Medicare PA requests244 **Right:** Use Medicare-specific appeal levels and timelines (redetermination → IRE → ALJ → MAC → Federal court)245 **Why:** Medicare has distinct appeal levels, timelines, and amount-in-controversy thresholds246247- **Wrong:** Failing to track PA expiration dates after authorization is granted248 **Right:** Monitor authorization validity periods and reauthorize before expiration if services are ongoing249 **Why:** Services rendered after PA expiration require new authorization — retroactive approval is rarely granted250251## 9. Decision Tree: PA Request Evaluation252253```254Is the service on the payer's PA-required list?255├── NO → No PA needed; proceed with service256└── YES257 ├── Is there an applicable NCD?258 │ ├── YES → Does the request meet NCD criteria?259 │ │ ├── YES → Approve (document NCD compliance)260 │ │ └── NO → Deny (cite NCD; appeal to ALJ if Medicare)261 │ └── NO → Check for LCD or plan-specific policy262 │ ├── LCD exists → Evaluate LCD criteria263 │ └── Plan policy exists → Evaluate plan criteria264 │ ├── Medical necessity met?265 │ │ ├── YES → Check step therapy266 │ │ │ ├── Step therapy satisfied → Approve267 │ │ │ └── Step therapy NOT satisfied268 │ │ │ ├── Exception applies? → Approve with exception269 │ │ │ └── No exception → Deny (cite step therapy)270 │ │ └── NO → Deny (cite medical necessity)271 │ └── Documentation incomplete?272 │ └── Pend for additional information273```274275## 10. Quick Reference: Denial Reason Categories276277| Category | CARC Code Range | Example | Recommended Action |278|----------|-----------------|---------|-------------------|279| Medical necessity not met | 50, 56 | Diagnosis does not support service | Appeal with clinical evidence |280| Step therapy not completed | 149 | Required prior drug not tried | Document prior treatments |281| Not a covered benefit | 96, 97 | Service excluded from plan | Formulary exception or plan change |282| Documentation insufficient | 16, 252 | Missing clinical notes | Resubmit with complete records |283| Experimental/investigational | 56 | Off-label use not approved | Cite peer-reviewed evidence |284| Out of network | 151 | Provider not in network | Network exception or referral |285| Duplicate authorization | 18 | PA already exists for service | Verify existing PA status |286287## 11. PA Turnaround Time Requirements288289| Request Type | Commercial (typical) | Medicare Part C | Medicare Part D |290|-------------|---------------------|-----------------|-----------------|291| Standard (non-urgent) | 15 calendar days | 14 calendar days | 72 hours (standard) |292| Expedited (urgent) | 72 hours | 72 hours | 24 hours |293| Retrospective | 30 calendar days | 30 calendar days | N/A |294| Extension (pend for info) | +14 days (one extension) | +14 days | +14 days |295296### Urgency Determination Rules297298A request qualifies as **expedited** when:2993001. Applying standard timeframe could seriously jeopardize the patient's life or health3012. Applying standard timeframe could jeopardize the patient's ability to regain maximum function3023. A physician indicates the request is urgent (physician attestation)3034. The patient is currently undergoing treatment that would be interrupted304305## 12. Quantity Limits and Site-of-Care Policies306307### 12.1 Quantity Limit Structures308309| Limit Type | Description | Example |310|-----------|-------------|---------|311| Per-fill limit | Maximum units per prescription fill | 30-day supply for controlled substances |312| Per-period limit | Maximum units over a time period | 9 fills per year for triptan medications |313| Lifetime limit | Maximum total units ever | Gene therapy — single administration |314| Diagnosis-based limit | Quantity varies by condition | Higher opioid limits for cancer pain |315316### 12.2 Site-of-Care Optimization317318Payers increasingly require lower-cost sites for infusion and injection therapies:319320```321Is the drug available for home infusion?322├── YES → Home infusion preferred (lowest cost)323│ ├── Patient clinically stable? → Approve home infusion324│ └── Patient requires monitoring? → Approve outpatient infusion center325└── NO → Is outpatient infusion center available?326 ├── YES → Outpatient preferred over hospital outpatient327 └── NO → Hospital outpatient department approved328```329330## 13. Regulatory Timeline: Key PA Reform Dates331332| Date | Regulation | Impact |333|------|-----------|--------|334| Jan 2024 | CMS Interoperability Rule (CMS-0057-F) finalized | Payers must implement FHIR PAS API |335| Jan 2026 | FHIR PAS API mandate effective | Payers must accept electronic PA via Da Vinci PAS |336| Jan 2026 | PA decision transparency | Payers must provide specific denial reasons and applicable criteria |337338### Gold Carding Programs339340Several states require payers to exempt providers from PA if they demonstrate ≥90% approval rate for a specific service over 12 months. Exemption lasts 12 months, subject to audit, and is revoked if approval rate drops below threshold.